Previous Close | 31.15 |
1-Year Change | 152.84% |
6-Months Change | 75.99% |
3-Months Change | 27.66% |
Moving Avg (50d) | 25.159 |
Moving Avg (200d) | 19.514 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.72B |
Beta (3-Years) | 2.45 |
Revenue Growth (ttm) | 3676.56% |
Net Profit Margin (ttm) | -13.65% |
Return On Assets (ttm) | -7.82% |
EPS (ttm) | -0.27 |
PE Ratio (ttm) | -115.37 |
Dividend Yield | % |
Asset Description: | TG Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-11-11 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
30.527 | 29.592 | 28.969 | 28.035 | 26.477 | 24.92 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |